FDA MedWatch report: Lithium and neuroleptics in combination: The spectrum of neurotoxicity

Psychopharmacology Bulletin

Volumn 32, Issue 3, 1996, Pages 299-309

  Goldman, Stephen A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

classification; diagnosis; lithium; neuroleptic; neurotoxicity

Indexed keywords

AMOXAPINE; BROMPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; PERPHENAZINE; PROCHLORPERAZINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ARTICLE; CONSCIOUSNESS DISORDER; FOOD AND DRUG ADMINISTRATION; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MUSCLE HYPERTONIA; MUSCLE RIGIDITY; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; SCHIZOPHRENIA; TREMOR; ADULT; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; DRUG INTERACTION; FEMALE; MALE; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; CONSCIOUSNESS DISORDERS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; LITHIUM; MALE; MIDDLE AGED; MUSCLE HYPERTONIA;

EID: 0029908672     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Addonizio, G; Roth, SD; Stokes, PE; and Stoll, PM. Increased extrapyramidal symptoms with addition of lithium to neuroleptics. J. Nerv. Ment. Dis. 176:682-685, 1988.
2. Addonizio, G; Susman, VL; and Roth, SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am. J. Psychiatry 143:1587-1590, 1986.
3. Adityanjee; Singh, S; Singh, G; and Ong, S. Spectrum concept of neuroleptic malignant syndrome. Br. J. Psychiatry 153:107-111, 1988.
4. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am. J. Psychiatry 151(Suppl.):1-36, 1994.
5. Arana, GW, and Hyman, SE. Handbook of Psychiatric Drug Therapy. 2nd ed. Boston, MA: Little, Brown and Company, 1991.
6. Caroff, SN. The neuroleptic malignant syndrome. J. Clin. Psychiatry 41:79-83, 1980.
7. Caroff, SN, and Mann, SC. Neuroleptic malignant syndrome. Psychopharmacol. Bull. 24:25-29, 1988.
8. Caroff, SN, and Mann, SC. Neuroleptic malignant syndrome. Med. Clin. North Am. 77:185-202, 1993.
9. Caroff, SN; Mann, SC; Lazarus, A; Sullivan, K; and Macfadden, W. Neuroleptic malignant syndrome: Diagnostic issues. Psychiatr. Ann. 21:130-147, 1991.
10. Conlon, P. The spectrum concept of neuroleptic toxicity (letter). Am. J. Psychiatry 143:811, 1986.
11. Fogel, BS, and Goldberg, RJ. Neuroleptic malignant syndrome (letter). N. Engl. J. Med. 313:1292, 1985.
12. Gelenberg, AJ, and Jefferson, JW. Lithium tremor. J. Clin. Psychiatry 56:283-287, 1995.
13. Goldman, SA. Lithium and neuroleptics in combination: Is there enhancement of neurotoxicity leading to permanent sequelae? J. Clin. Pharmcol., in press.
14. Groleau, G. Lithium toxicity. Emerg. Med. Clin. North Am. 12:511-531, 1994.
15. Gurrera, RJ; Chang, SS; and Romero, JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J. Clin. Psychiatry 53:56-62, 1992.
16. Hermesh, H; Aizenberg, D; Weizman, A; Lapidot, M; Mayor, C; and Munitz, H. Risk for definite neuroleptic malignant syndrome: A prospective study in 223 consecutive inpatients. Br. J. Psychiatry 161:254-257, 1992.
17. Kane, JM. Schizophrenia: Somatic treatment. In: Kaplan, HI, and Sadock, BJ, eds. Comprehensive Textbook of Psychiatry Vol. 1, 5th ed. Baltimore, MD: Williams and Wilkins, 1989. pp. 777-792.
18. Komhuber, J, and Weller, M. Neuroleptic malignant syndrome. Curr. Opin. Neurol. 7:353-357, 1994.
19. Levenson, JL. Neuroleptic malignant syndrome. Am. J. Psychiatry 142:1137-1145, 1985.
20. Levinson, DF, and Simpson, GM. Neuroleptic-induced extrapyramidal symptoms with fever Heterogeneity of the 'neuroleptic malignant syndrome.' Arch. Gen. Psychiatry 43:839-848, 1986.
21. Modestin, J; Toffler, G; and Drescher, JP. Neuroleptic malignant syndrome: Results of a prospective study. Psychiatry Res. 44:251-256, 1992.
22. Murphy, DJ; Gannon, MA; and Hartman, ML. Extrapyramidal symptoms with addition of lithium to neuroleptics (letter). J. Nerv. Ment. Dis. 177:708, 1989.
23. Nasrallah, HA; Churchill, CM; and Hamdan-Allan, GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am. J. Psychiatry 145:1455-1456, 1988.
24. Nayak, RK; Doose, DR; and Vasavan Nair, NP. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J. Clin. Pharmacol 27:144-150, 1987.
25. O'Dwyer, A-M, and Sheppard, NP. The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. Psychol. Med. 23:323-326, 1993.
26. Pope, HG Jr; Keck, PE Jr; and McElroy, SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am. J. Psychiatry 143:1227-1233, 1986.
27. Reilly, JJ; Crowe, SF; and Lloyd, JH. Neuroleptic toxicity syndromes: A clinical spectrum. Aust. N. Z. J. Psychiatry 25:499-505, 1991.
28. Schatzberg, AF, and Cole, JO. Manual of Clinical Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press, Inc., 1991.
29. Schou, M. The recognition and management of lithium intoxication. In: Johnson, FN, ed. Handbook of Lithium Therapy. Baltimore, MD: University Park Press, 1980. pp. 394-402.
30. Spring, G, and Frankel, M. New data on lithium and haloperidol incompatibility. Am. J. Psychiatry 138:818-821, 1981.
31. Totten, VY; Hirschenstein, E; and Hew, P. Neuroleptic malignant syndrome presenting without initial fever: A case report. J. Emerg. Med. 12:43-47, 1994.
32. Vasavan Nair, NP; Suranyi-Cadotte, B; Schwarte, G; Thavundayil, JX; Achim, A; Lizondo, E; and Nayak, R. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: Efficacy, safety, and dosage equivalence. J. Clin. Psychopharmacol. 6(Suppl. 1):30S-37S, 1986.
33. Weissman, MM; Leaf, PJ; Tischler, GL; Blazer, DG; Kamo, M; Bruce, ML; and Florio, LP. Affective disorders in five United States communities. Psychol. Med. 18:141-153, 1988.
34. Woodbury, MM, and Woodbury, MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J. Am. Acad. Child Adolesc. Psychiatry 31:1161-1164, 1992.